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Objectives
To use a non-biased assay for circulating tumour cells (CTCs)
in patients with prostate cancer (PCa) in order to identify
non-traditional CTC phenotypes potentially excluded by
conventional detection methods that are reliant on antigen-
and/or size-based enrichment.
Patients and Methods
A total of 41 patients with metastatic castration-resistant PCa
(mCRPC) and 20 healthy volunteers were analysed on the
Epic CTC platform, via high-throughput imaging of DAPI
expression and CD45/cytokeratin (CK) immunoﬂuorescence
(IF) on all circulating nucleated cells plated on glass slides.
To conﬁrm the PCa origin of CTCs, IF was used for
androgen receptor (AR) expression and ﬂuorescence in situ
hybridization was used for PTEN and ERG assessment.
Results
Traditional CTCs (CD45/CK+/morphologically distinct)
were identiﬁed in all patients with mCRPC and we also
identiﬁed CTC clusters and non-traditional CTCs in patients
with mCRPC, including CK and apoptotic CTCs. Small
CTCs (≤white blood cell size) were identiﬁed in 98% of
patients with mCRPC. Total, traditional and non-traditional
CTCs were signiﬁcantly increased in patients who were
deceased vs alive after 18 months; however, only non-
traditional CTCs were associated with overall survival.
Traditional and total CTC counts according to the Epic
platform in the mCRPC cohort were also signiﬁcantly
correlated with CTC counts according to the CellSearch
system.
Conclusions
Heterogeneous non-traditional CTC populations are frequent
in mCRPC and may provide additional prognostic or
predictive information.
Keywords
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Introduction
Dissemination of cancer cells from primary sites into
circulation and seeding of metastases is the underlying cause
of mortality for most non-haematopoietic malignancies.
Detection and enumeration of circulating tumour cells
(CTCs) is associated with decreased progression-free survival
and overall survival for a variety of tumours, including
prostate cancer (PCa) [1–3]. Based on these ﬁndings, CTC
enumeration could be a valuable tool for disease response and
progression monitoring. Additionally, CTCs can also be
characterized for predictive biomarkers. Given that CTCs
circulate at very low concentrations (106–107) [4],
detection in millilitres of blood requires extremely sensitive
and speciﬁc methods. Numerous technologies have been
developed to this end [5,6], with the majority requiring an
enrichment step based on differences in various physical (size
and/or density) or biological variables (surface marker
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expression) to distinguish CTCs from surrounding
haematopoietic cells. For example, the CellSearch CTC
System, the only US Food and Drug Administration-cleared
method for CTC detection [7], requires cells to contain a
40,6-diamidino-2-phenylindole positive (DAPI)-intact nucleus,
lack expression of the haematopoietic marker CD45, express
epithelial cell adhesion molecule (EpCAM) and cytokeratin
(CK), and have a diameter >4 lm [7]. Enrichment
technologies, however, will potentially fail to capture non-
traditional tumour cells lacking the selected characteristic.
Indeed, recent reports using non-EpCAM or size-based
selection techniques have underscored this point, revealing
PCa CTCs with non-traditional phenotypes, describing
heterogeneity in size [8], epithelial marker expression [9], cell
integrity [10] and proliferation rate [11]; both between and
within individual patients. CTCs isolated from men with
metastatic PCa have also shown evidence of epithelial to
mesenchymal transition, via detection of epithelial to
mesenchymal transition-related transcription factors,
expression of N-cadherin and vimentin, and loss of CK and
E-cadherin expression [9]. The degree and scope of this
heterogeneity within PCa CTC populations is incompletely
described, however, as most approaches are only able to
assess heterogeneity in a single variable.
Numerous studies have identiﬁed a relationship between CTC
counts and disease progression or overall survival in
metastatic castrate-resistant PCa (mCRPC) [2,3]. These studies
have been based on single-parametric enrichment technologies
which probably miss non-traditional CTC phenotypes that
may have prognostic or therapeutic signiﬁcance. In the
present study, we use a non-biased assay technique (the Epic
CTC platform) that retains all nucleated cells and interrogates
them in a multiparametric fashion, analysing size, shape,
DAPI staining and immunoﬂuorescence (IF) antigen
characterization (typically CD45 and CK expression).
Concurrently, we evaluated both traditional (CD45, CK+,
morphologically distinct) and candidate non-traditional CTCs
for PCa-speciﬁc molecular aberrations, including androgen
receptor (AR) expression by IF, and PTEN deletion and ERG
rearrangement by ﬂuorescence in situ hybridization (FISH)
[12–15]. Through this approach, we show that patients with
mCRPC harbour a variety of non-traditional CTC phenotypes.
Patients and Methods
Sample Collection and Handling
Whole-blood samples were obtained from 41 unique patients,
required to have histologically or biochemically conﬁrmed
prostate adenocarcinoma and planned for initiation of a new
treatment for progressive mCRPC in the presence of castrate
levels of serum testosterone (<50 ng/dL [1.73 nmol/L]),
consistent with Prostate Cancer Clinical Trials Working
Group 2 (PCWG2) guidelines. After collection at the Royal
Marsden, Sutton, UK, samples were shipped to Epic Sciences
(San Diego, CA, USA) at ambient temperature. Sample
collection for this study was approved by the Royal Marsden
(London, UK) Research Ethics Committee (REC 04/Q0801/6)
and by the Royal Marsden Committee for Clinical Research.
Additionally, 21 samples were obtained from 20 consenting
healthy adults by the Institute of Cancer Research (London,
UK) or Epic Sciences, and processed in the same manner as
patient samples. All samples were collected with informed
consent. Patient and healthy volunteer demographics are
summarized in Table 1. The median (range) blood sample
transit time for patient samples was 32 (28–78) h. Additional
draws from select patients were evaluated as needed for FISH.
Table 1 Demographic and clinical characteristics of patients and healthy
volunteers at the time of study inclusion.
Patients with CRPC n = 41
Age, years
Median 70
Range 40–82
Serum PSA, ng/mL
Median 90
Range 2–2532
Lactate dehydrogenase, U/L
Median 170
Range 112–678
Albumin, g/L
Median 35
Range 24–42
Haemoglobin, g/dL
Median 12.2
Range 8.3–15.5
Sites of metastases, n (%)
Bone 39 (95)
Nodal 28 (68)
Visceral 13 (32)
ECOG performance score
0 6 (15)
1 33 (80)
2 2 (5)
Previous CRPC therapies, n
Median 3
Range 1–5
Previous therapies, n (%)
Bicalutamide 41 (100)
Docetaxel 26 (63)
Cabazitaxel 4 (10)
Abiraterone 14 (34)
Enzalutamide 3 (7)
Investigational agents 13 (32)
Healthy volunteers n = 20
Age, years
Median 33.5
Range 21–53
Sex
Male 10
Female 10
CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology
Group.
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Blood Sample Preparation and Storage
Upon sample receipt, red blood cells were lysed and nucleated
cells dispensed onto glass microscope slides according to
methods previously described [16–18]. Up to 12 slides were
prepared from each blood sample at 3 9 106 cells/slide. Slides
were then stored at 80 °C (stable for >1 year, A. Johnson,
unpublished data). The number of slides created from each
individual sample was determined by the volume of blood
received and the white blood cell (WBC) count.
Circulating Tumour Cell Identiﬁcation and Protein
Characterization on the Epic Platform
For CTC analysis, two slides from each patient sample were
thawed, then stained by IF to distinguish CTCs from WBCs,
as described previously [16–18]. In addition to DAPI, CD45
and CK, an additional antibody targeting the N-terminal
region of AR (clone D6F11; Cell Signalling Technology,
Danvers, MA, USA) was used, capable of detecting full-length
and LBD-truncated variants of the protein. Stained slides
were imaged on a high-speed ﬂuorescent imaging system.
Captured images were analysed using an automated algorithm
that characterizes each cell using >90 variables, including
protein expression and morphology to distinguish CTCs from
normal nucleated cells. All CTC candidates were then
reviewed by trained technicians, and CK+/CD45 cells with
intact, DAPI+ nuclei exhibiting tumour-associated
morphologies were classiﬁed as traditional CTCs. The trained
technicians were blinded as to whether the sample was from
a patient with PCa or healthy donor. Candidate CTCs that
did not meet the criteria for traditional CTC, as described in
the Results section, were identiﬁed as CD45/CK cells with
abnormal morphology or apoptotic CTCs (CD45 with
characteristic nuclear fragmentation or condensation). In a
separate subsequent analysis, cell morphological
characteristics, including cell area, were determined for each
CTC using Epic proprietary software. Analysis was reviewed
by a Board-certiﬁed Anatomical Pathologist with experience
in genitourinary pathology and molecular characterization of
mCRPC (S.A.T.) to conﬁrm cancer origin.
Circulating Tumour Cell Analysis via CellSearch
Assay
Circulating tumour cell isolation and enumeration were
carried out using the CellSearchTM system (Janssen
Diagnostics, Raritan, NJ, USA) according to the
manufacturer’s instructions. Blood samples were drawn into
CellSaveTM tubes (Janssen Diagnostics) and samples were
kept at room temperature and processed within 72 h of
collection. To calculate the CTC count, 7.5 mL of blood
was enriched immunomagnetically using anti-EpCAM
antibodies, followed by ﬂuorescent labelling and individual
capture using a four-colour semi-automated ﬂuorescent
microscope. The images were then presented to trained
operators, who selected cells that met the deﬁnition of
CTCs. The criteria used to deﬁne a CTC include round to
oval morphology, size >5 lm, a visible nucleus (DAPI+),
positive staining for CK 8,18 and/or 19 (phycoerythrin)
and negative staining for CD45 (allophycocyanin). Results
were expressed as the number of cells per 7.5 mL of blood.
Circulating Tumour Cell Fluorescence in situ
Hybridization Analysis
After CTC IF analysis, a subset of slides with a sufﬁcient
number of CTCs was tested for PTEN loss or ERG
rearrangements by FISH. Coverslips were removed and slides
were hybridized using a two-color probe solution targeting
either PTEN and chromosome 10 centromere (CC10) DNA
sequences or regions ﬂanking 50 and 30 ERG (Cymogen Dx,
New Windsor, NY, USA). After processing, slides were
counterstained with DAPI and mounted with an anti-fade
mounting medium. Epic software was used to relocate CTCs
for scoring. A minimum of 20 WBCs on each slide were also
scored as internal controls.
PTEN loss was deﬁned as a cell containing fewer PTEN
signals than CC10 signals or only one of each signal (loss
of chromosome 10). Cells with no PTEN signals and at
least one CC10 signal were classiﬁed as homozygous PTEN
loss. Heterozygous PTEN loss cells contained at least one
PTEN signal and either more CC10 signals than PTEN or
one PTEN signal and one CC10 signal. Cells with a 1:1
ratio of PTEN:CC10 and at least two of each signal were
considered PTEN non-deleted. ERG rearrangements can
present as a split of the 50 and 30 FISH signals
(representing ERG fusions though insertion, inversion or
translocation) or as a deletion of the 50 FISH signal
(representing TMPRSS2:ERG fusions through deletion of the
intervening region on chromosome 21). Hence, cells were
considered ERG-rearranged if a separation of at least one
pair of 50 and 30 ERG signals (by a distance of at least two
signal diameters) or a deletion of at least one 50 ERG
signal was observed. Cells in which all 30 ERG signals had
a corresponding 50 ERG signal within two signal diameters
were considered ERG non-rearranged.
Statistical Analysis
Correlations/associations of traditional and non-traditional
CTC counts and clinicopathological variables were assessed
by Spearman rank correlation, two-sided Mann–Whitney
tests, Kruskal–Wallis tests or Kaplan–Meier analysis using
MEDCALC v 15.6 (MedCalc Software bvba, Belgium). Area
under the curve from receiver–operator characteristic (ROC)
curves was determined using MEDCALC v 15.6 for
traditional and non-traditional CTC counts for predicting
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mCRPC vs healthy volunteer status. Youden index CTC/mL
threshold, value and CTC thresholds with sensitivity and
speciﬁcity at 100% speciﬁcity and sensitivity, respectively,
were determined as part of the ROC analysis. Kaplan–Meier
analysis was performed by stratifying patients per CTC type
into those with ≤ vs >median CTC count. For all tests,
P values <0.05 were considered signiﬁcant.
Results
Detection of Traditional Circulating Tumour Cells in
Patients with Metastatic Castration-Resistant
Prostate Cancer
A total of 41 blood samples from 41 patients with mCRPC
and 21 blood samples from 20 healthy volunteers were
analysed. Patient and healthy volunteer demographics are
shown in Table 1. An average of 11 slides per patient were
plated (range 4–16) from a mean (range) blood volume of 7.0
(3.68–7.83) mL per patient. Traditional CTCs were deﬁned
(described previously [16–18]) as cells with an intact, DAPI-
positive nucleus lacking features of apoptosis, absence of
CD45 staining (CD45) and positive CK staining (CK+;
Fig. 1). Additionally, traditional CTCs were required to have
characteristic cytomorphological features consistent with
malignancy (including nucleomegaly, nuclear membrane
irregularity, eccentric cytoplasmic distribution, and polygonal/
elongated cell shapes) [16–19]. Using this traditional CTC
deﬁnition, 41/41 (100%) patients with mCRPC had detectable
traditional CTCs (median [range] 5 [1–121]/mL) and 22/41
(54%) had >4/mL. When two or more adjacent traditional
CTCs were identiﬁed, they were classiﬁed as CTC clusters.
CTC clusters were detected in 7/41 (17%) patients (median
[range] 0 [0–6]/mL; Fig. 1).
Of 20 healthy volunteers tested, none had >4 events in 1 mL
meeting the deﬁnition for a traditional CTC and 5(25%) had
1–4/mL (median [range] 0 [0–4]/mL; Fig. 2 for representative
events in healthy volunteers). CTC clusters were not detected
in healthy volunteer samples. Figure 3 shows the frequency of
traditional CTCs and CTC clusters in patient samples
compared with healthy volunteer samples.
An ROC curve analysis of traditional CTC counts, CTC
clusters and other non-traditional CTCs as described below
was performed to discriminate healthy volunteers from
patients with mCRPC, although this is not the intended use
of the assay (Table 2).
Phenotypic and Molecular Characterization of
Traditional Circulating Tumour Cells
Overexpression of AR, loss of PTEN, and ERG rearrangements
(most commonly resulting in TMPRSS2:ERG gene fusions) are
common molecular events in mCRPC and can be used to
conﬁrm that captured cells are CTCs, especially ERG
rearrangements that are PCa-speciﬁc [12–15]. AR expression
was evaluated in all patients with mCRPC and select healthy
volunteers. To generate a relative AR expression value for each
CTC, Epic’s software normalized AR expression in CTCs to
approximately 1 million surrounding CD45+ WBCs present
on the same slide, resulting in CTCs with AR expression
values ≥3.0 being considered positive. Across the 41 patients
with mCRPC, 28 (68%) had at least one AR-positive
traditional CTC/mL (range 0–96; Fig. 4A). The proportion of
AR+ to AR traditional CTCs was variable (Fig. 4B). Of six
healthy volunteer samples tested, none had >1 AR+ CTC/mL.
To further establish the prostatic origin of CTCs in our
cohort, we also assessed PTEN and ERG status by FISH.
First to determine assay speciﬁcity, we assessed PTEN and
ERG status of WBCs from patient slides tested by FISH. Of
120 patient WBCs evaluated for PTEN FISH, 3 (2.5%) and 0
(0.0%) cells were detected with PTEN heterozygous and
homozygous loss, respectively, resulting in 97.5–100%
speciﬁcity of PTEN FISH on the Epic platform. Of 220
patient WBCs evaluated with ERG FISH, 10 (4.5%) and 0
(0.0%) cells had a split signal or loss of the 50 probe
conﬁrming 95.5–100% speciﬁcity.
After IF staining for CTC and AR detection on the Epic
platform, CTCs from select patients with mCRPC were then
relocated and evaluated for PTEN and/or ERG FISH status.
PTEN deletions (heterozygous and/or homozygous) were
detected in traditional CTCs from four of ﬁve patients
evaluated (Table 3). Likewise, ERG rearrangements
(translocation and/or deletion) were identiﬁed in traditional
CTCs from ﬁve of six patients evaluated (Table 3).
Representative images of traditional CTCs with AR
expression and/or PTEN deletion or ERG rearrangement are
shown in Fig. 1. Among slides from healthy volunteers, none
had sufﬁcient detectable CTCs to perform PTEN or ERG
assessment.
Detection of Non-Traditional Circulating Tumour
Cells in Patients with Metastatic Castration-Resistant
Prostate Cancer
As described in detail below, we identiﬁed two categories of
cells with non-traditional phenotypes (in addition to CTC
clusters) that were potential CTCs: cells with weak or no CK
expression (CK CTCs), and cells with degenerative changes
and nuclear disintegration consistent with apoptosis
(apoptotic CTCs). All patients harboured circulating cells
with these non-traditional phenotypes (median 6/mL, range
1–101/mL). Four of 20 (20%) healthy volunteers had
circulating cells that met these expanded CTC criteria
(median 0/mL, range 0–5/mL) and 3/20 (15%) had cells with
AR positivity (median 0/mL per patient, range 0–4/mL).
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Figure 3 shows the frequency of non-traditional CTCs in
patient samples compared with healthy volunteer samples.
For all non-traditional CTCs, AR expression was evaluated by
IF and showed a wide variability similar to traditional CTCs
(Figure 4A). Representative images of non-traditional CTCs,
including those with PCa-speciﬁc molecular alterations, are
shown in Fig. 1.
Cytokeratin-Negative Circulating Tumour Cells
Cytokeratin intensity in CD45 circulating cells with
abnormal morphology varied widely across patients with
mCRPC (Fig. 4C). As with AR expression measurements,
relative CK expression values for every CTC were generated
by Epic’s software, normalizing CK expression in CTCs to
Traditional CTC
CompositeA
B
Dapi CK CD45 AR
CTC Cluster
Small CTC
CK- CTC
Apoptotic CTC
Traditional CTC
ERG 5’ deletion
CEP10
(PTEN deletion)
CEP10
(PTEN deletion)ERG 5’/3’
ERG 5’/3’ Split
Split
Traditional CTC Small CTC CK- CTC CK- CTC
Fig. 1 Patients with metastatic castration-resistant prostate cancer (mCRPC) harbour traditional and non-traditional circulating tumour cells (CTCs) with
prostate cancer-speciﬁc molecular alterations. (A) Representative immunoﬂuorescence (IF) image (1009 magniﬁcation) examples of traditional
and non-traditional CTCs in mCRPC patient samples (positive androgen receptor [AR] staining by IF is shown for each CTC). Traditional
(DAPI+/CD45/cytokeratin [CK]+/abnormal morphology), cluster (two or more adjacent traditional CTCs), small (DAPI+/CD45/CK+/small cellular area),
CK (DAPI+/CD45/CK/AR+/abnormal morphology), and apoptotic (DAPI+/CD45/CK+/nuclear disintegration/abnormal morphology) CTCs from
mCRPC patient samples are shown. (B) Example photomicrographs (4009 magniﬁcation) of ERG and PTEN gene alterations detected by ﬂuorescence
in situ hybridization (FISH) in traditional and non-traditional CTCs from mCRPC patient samples are shown (inset images (1009 magniﬁcation) show CTC
prior to FISH). PTEN deletions are indicated by loss of the PTEN locus green signal) in the presence of chromosome 10 centromeric signal (CEP 10, red).
ERG rearrangements can be identiﬁed by 50 deletion (resulting in loss of 50 green signal; far left panel) or by split 50/30 signals (centre and second from
right panel).
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approximately 1 million surrounding CD45+ WBCs present
on the same slide. CTCs with CK expression values ≥2.8 were
considered positive (signal ≥ 2.8-fold higher than background
WBCs). Hence, we deﬁned non-traditional CK CTCs as
CD45 circulating cells with morphological distinction and/or
AR positivity, but CK intensity <2.8. Such CK CTCs were
identiﬁed in 34/41 (83%) patients with mCRPC (median 2
CK CTC/mL, range 0–20). Amongst patients with CK
CTCs, 26 (76%) had at least one AR+ CK CTC/mL (range
0–20). The proportion of CK+/CK CTCs varied across the
cohort, with two patients demonstrating a CTC population
that was predominantly CK (Fig. 4D). Of healthy volunteers
evaluated, none had >1 CD45/CK cell/mL. PTEN FISH
was performed on ﬁve representative patients with CK- CTCs
and we were able to evaluate 18 CK- CTCs from three
patients (Table 3). Of three patients with evaluable CK-
CTCs, PTEN deletions were identiﬁed in one patient, with 5/9
(56%) CK- CTCs showing PTEN deletion. PTEN deletions
were also detected in 4/11 (36%) traditional CTCs from this
patient. ERG FISH was performed on six representative
patients with CK- CTCs and we were able to evaluate 26 CK-
CTCs from ﬁve patients. Of ﬁve patients with evaluable CK-
CTCs, ERG rearrangements were identiﬁed in three patients,
with 3/26 (12%) CK- CTCs showing ERG rearrangement.
ERG rearrangements were also detected in 18/108 (17%)
traditional CTCs from these three patients.
Apoptotic and Small Circulating Tumour Cells
CD45/CK+ cells with nuclear fragmentation or
condensation characteristic of apoptosis were also observed
across the mCRPC cohort. These cells, which we classiﬁed
as non-traditional apoptotic CTCs, were detected in 40/41
(98%) of patients with mCRPC (median 4/mL, range 0–92/
mL) as shown in Fig. 3. Of the 40 patients with apoptotic
CTCs, 31 (78%) had at least one AR+ apoptotic CTC/mL
(range 0–60/mL). Similar to the other categories of non-
traditional CTCs, the frequency of apoptotic CTCs varied
among patients with mCRPC, with 11/41 (27%) patients
Traditional CTC
Apoptotic CTC
CK-, AR+ CTC
Fig. 2 Circulating tumour cell (CTC)-like cells detected in healthy
volunteers. Representative immunoﬂuorescence (IF) examples (1009
magniﬁcation) of traditional and non-traditional CTC-like cells in healthy
volunteer samples. Traditional (DAPI+/CD45/cytokeratin [CK]+/abnormal
morphology), CK (DAPI+/CD45/CK/androgen receptor (AR)+/
abnormal morphology), and apoptotic (DAPI+/CD45/CK+/nuclear
disintegration/abnormal morphology) CTC-like cells from healthy
volunteers are shown. Blue = DAPI, green = CD45, Red = CK, White = AR.
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Fig. 3 Circulating tumour cell (CTC) incidence in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with healthy
volunteers. (A) The number of traditional CTCs, CTC clusters, cytokeratin (CK) CTCs, apoptotic CTCs and all CTC candidates (traditional, clusters, CK,
and apoptotic CTCs)/mL identiﬁed in healthy volunteers and mCRPC patient samples are plotted. Black lines indicate the median CTCs/mL. (B) Range,
median, and mean CTCs/mL in mCRPC patient samples for all categories are given.
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exhibiting CTC populations composed primarily of
apoptotic CTCs (Fig. 4E). As a result of nuclear
fragmentation or disintegration, apoptotic CTCs were not
amenable to FISH analysis.
We then used Epic software to objectively measure the total
cell area of each CTC to elucidate the subpopulations of CTCs
in patient samples that were similar in size to (or smaller
than) WBCs, that could potentially be missed by size or
density enrichment strategies for CTC isolation.
Approximately 300 patient WBCs were used to generate the
median and interquartile ranges for WBC area (75 lm2 and
64–90 lm2, respectively). We therefore used a cell area
≤90 lm2 to deﬁne a small CTC (Fig. 5A). Using this
approach, cell area of traditional and non-traditional CTC
subtypes was evaluated for 40/41 patient samples (one sample
was not evaluable by this method and was omitted from
analysis). Apoptotic CTCs were omitted from analysis because
of poor segmentation caused by fragmented cell morphology.
We observed a wide range of CTC sizes within individual
patients and across the cohort of patients with mCRPC using
this objective assessment, with small CTCs detectable in 39/40
(97.5%) patients with mCRPC. CTCs detected in patients with
mCRPC had a median (range) cell area of 99.0 (28.9–1631.0)
lm2. The proportion of small CTCs (CTCs with cell area
≤90 lm2) is shown for each patient in Fig. 5B, with 17/40
(42.5%) patients exhibiting CTC populations composed
predominantly of small CTCs. Small CTCs were evaluated in
select patient samples by FISH for ERG and PTEN aberrations
(Table 3). ERG FISH was performed on six patients with small
CTCs and we were able to evaluate 27 small CTCs from three
patients. Of these, ERG rearrangements were detected in one
patient in 6/23 (26%) small CTCs. ERG rearrangements were
also detected in 18/73 (25%) traditional CTCs (non-small)
from this patient. The size of small CTCs precluded
interpretation of PTEN deletions in all but three small CTCs
in two patients, which were wild-type. Examples of small
CTCs harbouring AR positivity by IF or ERG alterations by
FISH are shown in Fig. 1. Examples of small CTCs harbouring
AR positivity by IF or ERG alterations by FISH are shown in
Fig. 1.
Clinical Signiﬁcance of Circulating Tumour Cell
Types
Although the main focus of the present study was to deﬁne
the morphological and phenotypic range of CTCs in patients
with mCRPC using an unbiased approach complemented by
molecular characterization, we also assessed associations
between traditional and non-traditional CTC types and
clinicopathological variables (serum PSA, lactate
dehydrogenase, albumin and haemoglobin levels, as well as
previous treatment regimens and presence of visceral
metastasis). Importantly, as shown in Fig. 6A, this analysis
showed that counts of all CTC types detected by the Epic
platform (traditional, CTC clusters and each non-traditional
CTC type, as well as the sum of all CTCs) are signiﬁcantly
correlated with each other, ranging from Spearman rank
correlation (rs) = 0.35 for apoptotic CTC and CTC cluster
counts (P = 0.03), to rs=0.72 for traditional CTC and
apoptotic CTC counts (P < 0.001). Interestingly, there was no
signiﬁcant correlation between any CTC type count and
serum PSA levels; however, counts of CTC types other than
CTC clusters were signiﬁcantly associated with high lactate
dehydrogenase and low albumin, two important prognostic
variables. Likewise, both all CTC (sum of traditional CTCs,
CTC clusters, apoptotic CTCs and CK CTCs) and apoptotic
CTC counts were signiﬁcantly associated with the presence of
visceral metastasis (Fig. 6B). We did not identify a statistically
signiﬁcant difference between any CTC type count and
previous treatment regimen.
Next, we assessed correlations between CTC counts
according to the CellSearch CTC System and the Epic
platform in the mCRPC cohort. Importantly, as shown in
Table 4, we observed strong correlation between traditional
CTC counts according to CellSearch and traditional CTCs
Table 2 Receiver–operator characteristic curve analysis of circulating tumour cell counts for discriminating healthy volunteers and patients with
metastatic castration-resistant prostate cancer.
CTC type ROC Youden index 100% sensitivity 100% speciﬁcity
Area under
the curve
95% CI Value CTC/mL
threshold
CTC/mL
threshold
Speciﬁcity CTC/mL
threshold
Sensitivity
All CTCs 0.96 (0.88–0.99) 0.76 >4 >0 71% >9 56%
Traditional CTCs 0.93 (0.84–0.98) 0.71 >0 >0 71% >4 54%
Apoptotic CTCs 0.91 (0.81–0.97) 0.74 >0 N/A N/A >5 39%
CK CTCs 0.91 (0.81–0.97) 0.78 >0 N/A N/A >1 63%
CTC clusters 0.59 (0.45–0.71) 0.17 >0 N/A N/A >0 17%
CK, cytokeratin; CRPC, castration-resistant prostate cancer; CTC, circulating tumour cell; ROC, receiver–operator characteristic. ROC curves were generated from CTC/mL counts
for indicated CTC types (all CTCs is the sum of the other four types) for predicting CRPC status in 21 healthy volunteer samples (from 20 patients) and 41 CRPC samples. Cell size
was not included in this analysis (all categories may include small nuclear-sized CTCs). Area under the curve and 95% CIs are given, along with Youden index values and CTC/mL
thresholds. CTC/mL thresholds for 100% sensitivity and speciﬁcity are given, along with corresponding speciﬁcity and sensitivity.
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according to the Epic platform in the patients with mCRPC
(Pearson’s correlation r = 0.78, P < 0.001). Likewise, we also
observed signiﬁcant correlations between CellSearch CTC
counts and apoptotic (Pearson’s correlation r = 0.91, P <
0.0001) or CK CTC counts (r = 0.39, P = 0.02) with the
Epic platform (Table 4). No signiﬁcant correlation was
observed between CellSearch CTC counts and CTC cluster
counts (r = 0.07, P = 0.68) according to the Epic
platform, although CTC clusters were infrequently observed
in our cohort. Importantly, we identiﬁed a strong, signiﬁcant
correlation between CellSearch CTC counts and total CTC
counts with the Epic platform (r = 0.89, P < 0.001;
Table 4).
Lastly, to provide preliminary insight into associations with
clinical outcome, we determined CTC counts with the Epic
platform in patients with mCRPC who were alive and those
who were dead after 18 months (40 of 41 patients with
Fig. 4 Androgen receptor (AR) and cytokeratin (CK) expression by immunoﬂuorescence varies across traditional and non-traditional circulating tumour
cell (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) patient samples. AR (A&B) and CK (C&D) intensity distribution across traditional
and non-traditional CTCs per patient. The dashed lines at 3 (A) and 2.8 units (C) indicate the threshold for AR and CK positivity, respectively. Charts B
and D show the percentage of all CTCs/mL (traditional and non-traditional) with or without (B) AR or (D) CK expression per patient. (E) The percentage
of apoptotic and non-apoptotic CTCs/mL per patient.
Table 3 Fluorescence in situ hybridization characterization of prostate cancer (PCa)-speciﬁc molecular alterations (PTEN deletions top; ERG
rearrangements bottom) in phenotypically diverse CTCs in patients with metastatic castration-resistant PCa.
Patient Cell type PTEN evaluable
cells, n
AR+ cells, % PTEN heterozygous
cells, n
PTEN homozygous
cells, n
PTEN deletion
cells*, %
V4004† Traditional 7 14 2 0 29
CK 0 N/A N/A N/A N/A
Small 0 N/A N/A N/A N/A
V5035 Traditional 32 0 1 0 3%
CK 4 25 0 0 0
Small 1 0 0 0 0
V5042† Traditional 11 36 0 4 37
CK 9 44 1 4 56
Small 2 0 0 0 0
V5131 Traditional 12 0 1 1 17
CK 5 0 0 0 0
Small 0 N/A N/A N/A N/A
V5055 Traditional 13 0 0 0 0
CK 0 N/A N/A N/A N/A
Small 0 N/A N/A N/A N/A
Patient Cell type ERG evaluable
cells, n
AR+ cells, % ERG 50 deletion
cells, n
ERG 50/30 split
cells, n
ERG rearranged
cells‡, %
V4048 Traditional 11 0§ 0 0 0
CK 0 N/A N/A N/A N/A
Small 0 N/A N/A N/A N/A
V5025† Traditional 73 73 6 12 25
CK 10 90 0 0 0
Small 23 48 2 4 26
V5083 Traditional 35 63 4 7 31
CK 2 100 0 1 50
Small 3 0 0 0 0
V5085† Traditional 64 94 0 4 6
CK 6 83 0 1 17
Small 0 N/A N/A N/A N/A
V5106 Traditional 9 56 0 3 33
CK 1 100 0 1 100
Small 0 N/A N/A N/A N/A
V5131† Traditional 21 0 0 3 14
CK 7 0 0 0 N/A
Small 1 100 0 0 N/A
AR, androgen receptor; CK, cytokeratin. Fluorescence in situ hybridization (FISH) analysis for prostate-cancer speciﬁc alterations was performed on selected patients. The percentage
of circulating tumour cells (CTCs; stratiﬁed by type) with AR positivity by immunoﬂuorescence is given for patients assessed for PTEN loss (top panel) or ERG rearrangement
(bottom) by FISH. False-positive PTEN heterozygous and homozygous rate in white blood cells (WBCs) 2.5% (3/120 WBCs) and 0% (0/120 WBCs), respectively. False-positive ERG
50 deletion and 50/30 split rate 0% (0/220 WBCs) and 4.5% (10/220 WBCs), respectively. *Including both heterozygous and homozygous cells; †Additional slides beyond the standard
two slides were used for FISH evaluation; ‡Both 50 deletion and 50/30 split cells; §Three cells were unevaluable for AR expression.
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sufﬁcient follow-up). As shown in Fig. 6C, total, traditional
and non-traditional (clusters, apoptotic and CK) CTC
counts were signiﬁcantly higher in patients who had died
compared with those who were alive at 18 months (Mann–
Whitney test, P = 0.02, P = 0.03 and P = 0.04, respectively).
On Kaplan–Meier analysis of all 41 patients, the number of
non-traditional CTCs was signiﬁcantly associated with
overall survival (> vs ≤median CTC count; P = 0.03;
Fig. 4D). Results for individual non-traditional CTC types
are shown in Fig. 7. Interestingly, there were 14 patients
with <5 CTCs detected by the CellSearch assay, of which
four were deceased at 18 months; each of these deceased
patients had non-traditional CTC cells, as detected by the
Epic platform.
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Fig. 5 Circulating tumour cell (CTC) size varies greatly across patients with metastatic castration-resistant prostate cancer (mCRPC). (A) Cellular area
(lm2) per CTC as calculated by Epic software for each patient is plotted. White blood cell (WBC) size frequency distribution curve was generated by
measuring the cellular area of approximately 300 normal WBCs (right side). The blue dashed line represents the median WBC area (75 lm2). Red and
green dashed lines indicate WBC size cut-offs equal to the 25th (64 lm2) and 75th (90 lm2) percentile, respectively. Traditional CTCs (blue), CTC
clusters (green) and CK CTCs (purple) are indicated according to the legend. Apoptotic CTCs were omitted from analysis because of poor
segmentation of fragmented nuclei in these cells. (B) The percentage of all CTCs for each patient with area greater than (non-small CTC; green) or
less than the WBC 75th percentile (small CTC; red) is plotted. *Sample 5037 was not evaluable and is not included in panel A.
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Fig. 6 Associations of circulating tumour cell (CTC)/mL counts and clinicopathological variables. (A) Spearman rank correlation (rs) matrix of CTC/mL
counts (all = summed traditional, clusters, CK and apoptotic) and clinicopathological variables for the 41 patients with metastatic castration-resistant
prostate cancer (mCRPC) in our cohort. Correlations are given and indicated according to the colour scale in the legend). Statistical signiﬁcance of
each comparison is indicated by the cell border thickness according to the legend. (B) Signiﬁcant (P < 0.05, Mann–Whitney test) associations between
CTC counts (and clinicopathological variables) with the presence/absence of visceral metastases are shown. (C) All, traditional and non-traditional
CTC counts stratiﬁed by patient status (dead vs alive) at 18 months are plotted (40 of 41 patients evaluable at that time point). P values from Mann–
Whitney tests are shown. (D) Kaplan–Meier analysis for all, traditional and non-traditional CTC counts for overall survival time for all 41 patients. For each
CTC type, patients were stratiﬁed by having > or ≤median CTC count/mL. Log-rank test P values are shown.
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Discussion
To characterize the phenotypic diversity of CTCs in mCRPC,
we used the Epic platform to characterize all nucleated cells
from whole-blood samples [20]. Using DAPI, CD45, CK and
AR IF, we identiﬁed and morphologically characterized cells
with cancer-associated features, irrespective of whether they
met the traditional CTC deﬁnition. We then used FISH and
slide scanning with single-cell resolution to conﬁrm that sub-
populations of non-traditional CTCs were PCa in origin. We
detected non-traditional CTCs in all patients, including CTC
clusters, small, apoptotic and/or CK CTCs. We also
observed intra-patient heterogeneity of AR and CK expression
and PTEN and ERG status consistent with a heterogeneous
model of advanced disease, as has been observed in recent
studies of CRPC assessing AR expression in CellSearch-
isolated CTCs, metastatic tissues assessed by whole-genome
sequencing, and circulating cell-free DNA assessed using
targeted next-generation sequencing [21–23].
Although non-traditional CTC counts correlated with
traditional CTC counts, substantial variation in the
proportions of traditional to non-traditional CTCs were
observed. Importantly, some CTCs we identiﬁed could be
missed by CTC detection platforms using antigen capture (i.e.
EpCAM or CK) or size selection (such as ﬁltration). Similarly,
Table 4 Circulating tumour cell counts according to the Epic vs CellSearch platforms in patients with metastatic castration-resistant prostate cancer.
Patient CellSearch Epic CTC counts
CTCs/7 mL Traditional CTCs/mL CTC Clusters /mL CK CTCs/mL Apoptotic CTCs/mL All CTCs/mL
V4002 NA 2 0 1 1 4
V4004 2 9 3 1 6 19
V4030 NA 7 0 1 7 15
V4045 NA 1 0 10 2 13
V4048 12 9 0 2 9 20
V4082 5 1 0 2 3 6
V5025 157 54 1 11 5 71
V5031 NA 1 0 1 3 5
V5035 1 57 6 14 10 87
V5037 0 4 0 3 2 9
V5039 27 6 0 2 4 12
V5042 285 8 0 1 14 23
V5054 11 1 0 2 4 7
V5055 52 26 2 3 6 37
V5058 1 1 0 3 1 5
V5061 6 3 0 2 4 9
V5066 NA 2 0 1 3 6
V5069 70 27 0 5 16 48
V5070 1 3 0 0 6 9
V5071 6 2 0 0 3 5
V5074 18 5 0 0 2 7
V5076 1 2 0 0 1 3
V5080 3 2 0 0 3 5
V5083 646 59 0 9 78 146
V5085 563 121 0 17 42 180
V5086 26 3 0 1 3 7
V5088 0 5 0 8 7 20
V5102 5 4 0 5 2 11
V5106 448 55 0 4 45 104
V5107 568 49 1 9 92 151
V5108 1 1 0 0 3 4
V5110 0 4 0 2 3 9
V5111 0 13 1 7 9 30
V5122 0 5 0 20 15 40
V5126 5 2 0 2 2 6
V5127 95 15 0 4 4 23
V5131 0 17 2 9 5 33
V5133 12 8 0 3 1 13
V5135 2 10 0 6 7 23
V5145 34 1 0 1 0 2
V5148 21 8 0 0 2 10
Correlation with CellSearch: 0.78 0.07 0.39 0.91 0.89
P <0.001 0.68 0.02 <0.001 <0.001
CK, cytokeratin; CTC, circulating tumour cell; NA, not available. CTC counts for 41 patients with metastatic castration-resistant prostate cancer as determined by the CellSearch and
Epic platforms are given. For Epic determined CTC counts, counts for traditional CTCs, non-traditional CTCs (CTC clusters, apoptotic CTCs and CK CTCs) and all CTCs (sum of
traditional and non-traditional CTCs) are given. Pearson correlation and P values of CellSearch counts with each Epic CTC category across the cohort are given below the table.
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Chen et al. [8], recently reported that EpCAM captured CTCs
(enriched using NanoVelcro Chips) in patients with mCRPC
showed variable nuclear size, and patients with visceral
metastases speciﬁcally showed elevated very small nuclear-
sized CTCs [8]. Our results suggest that in addition to
nuclear size variability, CTCs in patients with mCRPC show
considerable heterogeneity in nuclear organization, and CK
and AR expression.
CK+/CD45 cells were identiﬁed in a small minority of
healthy volunteer samples at low frequencies, with the
majority demonstrating low CK and AR expression. Given no
universally established reference range for the deﬁnition of
CTCs, nor a recognized pan-CTC marker, it is difﬁcult to
discern the relevance of these cells in healthy volunteers.
CTC-like cells can be detected in the blood of patients with
benign conditions as well as in those with early-stage disease
[24–26], and have been reported in labelled healthy
volunteers [27]. The ideal healthy volunteer or non-cancer
control population would be matched in age and
demographics, with conﬁrmed absence of malignancy. While
these caveats are impediments for using any CTC platform
for the primary diagnosis of PCa, the increased sensitivity
and speciﬁcity of the Epic platform for CTC detection could
be suited for acquiring prognostic and predictive information
in patients with mCRPC.
Detection of signiﬁcant non-traditional CTC populations
in patients with mCRPC is consistent with substantial
evidence supporting their existence and clinical relevance.
For example, CTCs postulated to have undergone
epithelial to mesenchymal transition, and displaying
reduced/no EpCAM or CK expression, have been
identiﬁed by multiple platforms using both cell lines and
patient samples [27–33]. These cells may be enriched for
multipotent cancer stem cells, with increased self-renewal
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Fig. 7 Associations of non-traditional circulating tumour cell (CTC)/mL counts in patients with metastatic castration-resistant prostate cancer and
overall survival (A-C). Individual non-traditional CTC type counts (CTC clusters (A), apoptotic CTCs (B), and cytokeratin [CK] CTCs (C) stratiﬁed by
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CTC type, patients were stratiﬁed by having > or ≤median CTC count/mL. Log-rank test P values are shown.
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and metastasis-forming capacity [34,35]. Although previous
studies demonstrate substantial heterogeneity of PTEN
deletion status in CTCs and CRPC tissue foci in a given
patient [12,36], ERG rearrangements have generally been
identiﬁed as a clonal alteration (when present) in both
CTCs and mCRPC tissue [12,21,37–39]. Possible
explanations for these apparently discrepant results include
increased sensitivity for traditional and non-traditional
CTCs (identiﬁed in the present study) that may represent
multiple clonal populations when compared with our
previous CellSearch-based study showing homogeneous
ERG status in traditional CTCs [12]. Also, our recent
study on circulating cell-free DNA in patients with
mCRPC supported the existence of both ERG rearranged
and wild-type clones in the same patient during disease
progression [23]. This contrasts with the observation that
multiple CRPC foci at autopsy in an individual patient
nearly always show homogeneous ERG status. Further
studies are required to interrogate this difference, which
we hypothesize could be informed by more comprehensive
genetic analysis of individual traditional and non-
traditional CTC populations.
Our cohort represents a single-institution mCRPC cohort and
the relatively small size in this non-uniformly treated initial
study limits the ability to draw robust conclusions on
associations between non-traditional CTCs and clinical
outcome. Likewise, additional studies are needed to
characterize the metastatic potential of distinct CTC classes.
Importantly, evaluation of these distinct CTC populations
described here in larger, well-deﬁned cohorts to inform on
their prognostic and predictive utility in mCRPC is now
warranted. In the present study, using pathological and
molecular biological approaches, we have described expanded
categories of CTC phenotypes in patients with mCRPC and
show that considerable heterogeneity exists within these
categories. These expanded CTC subtypes may provide novel
prognostic and predictive information for patients with
mCRPC, as well as other advanced cancers. Intriguing
preliminary clinical associations between mCRPC outcomes
and various CTC subpopulations will need to be assessed in
additional ongoing and planned studies to expand on our
study.
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